Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Modern Rheumatology

• Publication date

  2015-06-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/14397595.2014.987437PMID 25528863
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of Interleukin-1 Targeting Treatments in Patients with Familial Mediterranean Fever

  2015cited by this paper
• Treating inflammation by blocking interleukin-1 in humans.

  2013cited by this paper
• Efficacy and Safety of Biologic Treatments in Familial Mediterranean Fever

  2013cited by this paper
• Incomplete response to colchicine in M694V homozygote FMF patients.

  2012cited by this paper
• Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes

  2012cited by this paper
• Canakinumab induces remission in a patient with resistant familial Mediterranean fever.

  2012cited by this paper
• Application of the new pediatric criteria and Tel Hashomer criteria in heterozygous patients with clinical features of FMF

  2011cited by this paper
• Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature.

  2011cited by this paper
• The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis

  2011cited by this paper
• Anti-Interleukin 1 Treatment for Patients with Familial Mediterranean Fever Resistant to Colchicine

  2011cited by this paper
• Interleukin-1beta and the autoinflammatory diseases.

  2009cited by this paper
• Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine.

  2008cited by this paper
• The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever

  2007cited by this paper
• Colchicine Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and Consensus Statement

  2007cited by this paper
• Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization.

  2004cited by this paper
• Clinical differences between North African and Iraqi Jews with familial Mediterranean fever.

  1998cited by this paper

• Evaluation of biological treatment in pediatric patients with familial Mediterranean fever: a retrospective study of 832 patients

  2025cites this paper
• Real-World Experience with Canakinumab in Familial Mediterranean Fever: A Single-Center Study

  2025cites this paper
• Long-term safety profile and secondary effectiveness of canakinumab in pediatric rheumatic diseases: a single-center experience

  2024cites this paper
• A narrative review on the role of cytokines in the pathogenesis and treatment of familial Mediterranean fever: an emphasis on pediatric cases

  2024influential citation
• Efficacy and safety of anti‐interleukin‐1 in children with colchicine‐resistant familial Mediterranean fever

  2023cites this paper
• An Update on Familial Mediterranean Fever

  2023cites this paper
• The clinical role of anakinra in the armamentarium against familial Mediterranean fever

  2023cites this paper
• Efficacy and safety of anti-ınterleukin-1 treatment in familial Mediterranean fever patients: a systematic review and meta-analysis.

  2023cites this paper
• The effect of canakinumab treatment on growth parameters in children with familial Mediterranean fever

  2023cites this paper
• IL-1 inhibition in familial Mediterranean fever: clinical outcomes and expectations.

  2022cites this paper
• Ocular involvement in monogenic autoinflammatory disease: A systematic literature review.

  2021cites this paper
• Conventional and novel therapeutic options in children with familial Mediterranean fever: A rare autoinflammatory disease

  2021influential citation
• Real-Life Indications of Interleukin-1 Blocking Agents in Hereditary Recurrent Fevers: Data From the JIRcohort and a Literature Review

  2021cites this paper
• Amyloidosis and Glomerular Diseases in Familial Mediterranean Fever

  2021cites this paper
• IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives

  2021cites this paper
• Growth Parameters of Turkish Children With an Autoinflammatory Disease Before and After Canakinumab Treatment

  2020cites this paper
• Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry.

  2020cites this paper
• Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases.

  2020cites this paper
• The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review

  2020cites this paper
• A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever.

  2020cites this paper
• Effect of anti‐interleukin‐1 treatment on quality of life in children with colchicine‐resistant familial Mediterranean fever: A single‐center experience

  2020cites this paper
• Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever.

  2020cites this paper
• Do all colchicine preparations have the same effectiveness in patients with familial Mediterranean fever?

  2020cites this paper
• Ergebnisse der systematischen Literatursuche als Grundlage für die „evidenzbasierten Therapieempfehlungen für FMF-Patienten mit unzureichendem Ansprechen bzw. Unverträglichkeit auf Kolchizin“ der Gesellschaft für Kinder- und Jugendrheumatologie und der Deutschen Gesellschaft für Rheumatologie

  2020cites this paper
• [Results of the systematic literature search as basis for the "Evidence-based treatment recommendations for familial Mediterranean fever patients with insufficient response or intolerability to colchicine" of the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatolo

  2020cites this paper
• Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience.

  2020cites this paper
• Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review

  2019cites this paper
• Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases

  2019cites this paper
• Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis

  2019cites this paper
• Evidenzbasierte Therapieempfehlungen für das familiäre Mittelmeerfieber

  2019cites this paper
• Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)

  2019cites this paper
• Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients

  2019cites this paper
• Efficacy and safety of long-term treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine

  2019cites this paper
• Evidence-based treatment recommendations for familial Mediterranean fever . A joint statement by the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology

  2019cites this paper
• IL1-blocking therapy in colchicine-resistant familial Mediterranean fever

  2018influential citation
• Canakinumab treatment in children with familial Mediterranean fever: report from a single center

  2018cites this paper
• Anakinra for Colchicine‐Resistant Familial Mediterranean Fever: A Randomized, Double‐Blind, Placebo‐Controlled Trial

  2017cites this paper
• Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever

  2017cites this paper
• Canakinumab treatment in four children with colchicine resistant familial mediterranean fever.

  2017cites this paper
• Middle Initial Omitted From Author Name in the Article by Felson et al (Arthritis Rheumatol, February 2017)

  2017cites this paper
• Erratum

  2017cites this paper
• Cutaneous Manifestations of Systemic Disease

  2017cites this paper
• Canakinumab for the treatment of TNF-receptor associated periodic syndrome

  2017cites this paper
• Rezidivierende Monarthritiden kleiner Gelenke: atypisches Leitsymptom eines spät erkannten familiären Mittelmeerfiebers

  2017cites this paper
• Canakinumab for the treatment of familial Mediterranean fever

  2017cites this paper
• Correlation of Secretory Activity of Neutrophils With Genotype in Patients With Familial Mediterranean Fever

  2016cites this paper
• Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare.

  2016cites this paper
• Approach to the patients with inadequate response to colchicine in familial Mediterranean fever.

  2016cites this paper
• Biologic therapy in familial Mediterranean fever

  2016cites this paper
• The effect of colchicine and disease severity on physical growth in children with familial Mediterranean fever

  2016cites this paper
• Preclinical characterization and clinical development of ILARIS(®) (canakinumab) for the treatment of autoinflammatory diseases.

  2016cites this paper
• Canakinumab investigated for treating familial Mediterranean fever

  2016cites this paper
• Modulating Inflammatory Cytokines

  2016cites this paper
• Autoinflammatory disorders in Children

  2016cites this paper
• Current therapeutic options for managing familial Mediterranean fever

  2015cites this paper